Efficacy and Safety of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects with Type 2 Diabetes Mellitus

被引：0
|
作者：
Terra, Steven G.
Somayaji, Veena
Teeter, John G.
Dai, Haiqing
Nguyen, Tu T.
Ghazzi, Mahmoud
机构：
来源：
DIABETES | 2009年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A134 / A135
页数：2
相关论文
共 50 条
  • [31] Metformin treatment of type 2 diabetes mellitus in pregnancy: update on safety and efficacy
    Polasek, Thomas M.
    Doogue, Matthew P.
    Thynne, Tilenka R. J.
    THERAPEUTIC ADVANCES IN DRUG SAFETY, 2018, 9 (06) : 287 - 295
  • [32] Efficacy and safety of canagliflozin in older subjects with type 2 diabetes mellitus
    Sinclair, A.
    Bode, B.
    Harris, S.
    Vijapurkar, U.
    Gassmann-Mayer, C.
    Fung, A.
    Shaw, W.
    Usiskin, K.
    Desai, M.
    Meininger, G.
    DIABETOLOGIA, 2013, 56 : S383 - S383
  • [33] Efficacy and Safety of Triple Therapy with SGLT-2 Inhibitor, DPP-4 Inhibitor, and Metformin in Type 2 Diabetes: A Meta-Analysis
    Li, Mengdi
    Wang, Sining
    Wang, Xiaoli
    ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2023, 29 (05) : 320 - 326
  • [34] Efficacy and Safety of Antihyperglycemic Agents Added to Metformin Monotherapy in Patients with Type 2 Diabetes
    Mearns, Elizabeth S.
    Sobieraj, Diana M.
    White, C. Michael
    Saulsberry, Whitney J.
    Doleh, Yunes
    Zaccaro, Eric
    Coleman, Craig I.
    DIABETES, 2015, 64 : A658 - A658
  • [35] Efficacy and Safety of Antihyperglycemic Agents Added to Metformin and Sulfonylurea Therapy in Type 2 Diabetes
    Coleman, Craig I.
    Saulsberry, Whitney J.
    White, C. Michael
    Kohn, Christine G.
    Lemieux, Steven
    Sihabout, Amanda
    Salamucha, Ilona
    Mearns, Elizabeth S.
    DIABETES, 2015, 64 : A654 - A654
  • [36] Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
    Raz, Itamar
    Chen, Yu
    Wu, Mei
    Hussain, Shehla
    Kaufman, Keith D.
    Amatruda, John M.
    Langdon, Ronald B.
    Stein, Peter P.
    Alba, Maria
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (02) : 537 - 550
  • [37] Synthesis and evaluation of camphor and cytisine-based cyanopyrrolidines as DPP-IV inhibitors for the treatment of type 2 diabetes mellitus
    Kuranov, S. O.
    Tsypysheva, I. P.
    Khvostov, M., V
    Zainullina, Liana F.
    Borisevich, S. S.
    Vakhitova, Yu V.
    Luzina, O. A.
    Salakhutdinov, N. F.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (15) : 4402 - 4409
  • [38] Safety, tolerability, pharmacokinetics and pharmacodynarnics of SK-0403, a novel DPP-IV inhibitor, in healthy Japanese subjects
    Sunami, Yukiko
    Yoshioka, Naoya
    Hayashi, Ichiro
    Ishida, Tsutomu
    Ishida, Tomu
    DIABETES, 2007, 56 : A128 - A129
  • [39] Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes (T2D)
    Scott, R
    Herman, G
    Zhao, P
    Chen, X
    Wu, M
    Stein, P
    DIABETES, 2005, 54 : A10 - A11
  • [40] QSAR studies on pyrrolidine amides derivatives as DPP-IV inhibitors for type 2 diabetes
    Xiaoyan Yang
    Minjie Li
    Qiang Su
    Milin Wu
    Tianhong Gu
    Wencong Lu
    Medicinal Chemistry Research, 2013, 22 : 5274 - 5283
12345